Abstracts Archive - Page 1374 of 2425 - ACR Meeting Abstracts

Abstract Number: 2527 • 2017 ACR/ARHP Annual Meeting
Increased Prevalence of Subclinical Atherosclerosis in Moderate-Severe Plaque Psoriasis Patients
Nuria Vegas-Revenga¹, José Luis Martín-Varillas¹, Susana Armesto², Marcos A González- López³, Virginia Portilla², Patricia Fuentevilla¹, Javier Rueda-Gotor², Carlos Fernández-Díaz¹, Lucia C. Domínguez-Casas¹, Belén Atienza-Mateo¹, Jose L. Hernández⁴, Ricardo Blanco¹, Miguel Angel González-Gay¹ and Alfonso Corrales¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Surrogate markers of subclinical atherosclerosis and cardiovascular (CV) mortality such as carotid plaques (CP), arterial stiffness (AS) and carotid intima-media thickness (c-IMT), have been…
Abstract Number: 2528 • 2017 ACR/ARHP Annual Meeting
Prevalence of Depression and Attention Deficit Hyperactivity Disorder in Female Patients at a Combined Psoriasis-Psoriatic Arthritis Center
Soumya M. Reddy¹, Rebecca Haberman², Eileen Lydon³, Andrea L. Neimann⁴, Malavika Attur³, Mark Butler⁵, Tanya M. Spruill⁵ and Jose U. Scher⁶, ¹Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ²Department of Medicine (*contributed equally), New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Dermatology, New York University School of Medicine, New York, NY, ⁵Department of Population Health, New York University School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis affecting multiple clinical domains. Untreated, PsA has the potential for significant morbidity and disability. Psychiatric disorders…
Abstract Number: 2529 • 2017 ACR/ARHP Annual Meeting
Appraisal of the Contest Questionnaire in the Screening for Psoriatic Arthritis
Amir Haddad¹, Joy Feld^1,2, Lihi Eder³, Idit Lavi⁴, Oxana Zlazhover⁵ and Devy Zisman^1,6, ¹Rheumatology Unit Carmel Medical Center, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴Epidemiology Unit Carmel Medical Center, Haifa, Israel, ⁵Bnei Zion Medical Center, Haifa, Israel, ⁶The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is critical to prevent poor outcome. Several validated screening questionnaires have been developed to identify PsA patients in…
Abstract Number: 2530 • 2017 ACR/ARHP Annual Meeting
Clinical Specialty Setting As a Determinant for Disease Management in Patients with Psoriatic Arthritis: An Interim Analysis of the Cross-Sectional Observational Study
Wolf-Henning Boehncke¹, Rudolf Horváth², Ediz Dalkiliç³, Sȏnia A L Lima⁴, Masato Okada⁵, Maja Hojnik⁶, Fabiana Ganz⁷ and Ennio Lubrano⁸, ¹Geneva University Hospital and University of Geneva, Geneva, Switzerland, ²Department of Pediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic, ³Department of Internal Medicine, Division of Rheumatology, Uludag University School of Medicine, Gorukle, Bursa, Turkey, ⁴ABC Medical School, Santo André, Brazil, ⁵Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁶AbbVie, Ljubljana, Slovenia, ⁷AbbVie AG, Baar, Switzerland, ⁸Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
Background/Purpose: Evidence suggests that timely and effective management can improve long-term outcomes in patients (pts) with psoriatic arthritis (PsA); however factors influencing treatment management decisions…
Abstract Number: 2531 • 2017 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry
Philip J Mease¹, Jacqueline B. Palmer², Mark Lebwohl³, Chitra Karki⁴, George W. Reed⁵, Carol J. Etzel⁶, Jeffrey D. Greenberg⁷ and Philip S. Helliwell⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷New York University School of Medicine, New York, NY, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire developed to help identify psoriatic arthritis (PsA) at an early stage, with a score…
Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3. The objective of the…
Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
Abstract Number: 2534 • 2017 ACR/ARHP Annual Meeting
the Relationship between Biological Therapy, Work Productivity, and Activity Impairment in Patients with Psoriatic Arthritis: Prospective Multicentre Observational Study
Jiri Stolfa¹, Tomas Mlcoch², Jan Tuzil², Liliana Sedova³, Jitka Jircikova⁴, Monika Gregova⁵, Tomas Dolezal⁴ and Karel Pavelka⁶, ¹Instituite of Rheumatology Prague, Rheumatology, Prague, Czech Republic, ²Institute of Health Economics and Technology Assessment (iHETA), Statistician, Prague, Czech Republic, ³Institute of Rheumatology Prague, rheumatologist, Prague, Czech Republic, ⁴Institute of Health Economics and Technology Assessment (iHETA), statistician, Prague, Czech Republic, ⁵Instituite of Rheumatology Prague, rheumatologist, Prague, Czech Republic, ⁶Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Psoriatic arthritis (PsA) is a progressive disease bringing substantial socioeconomic burden. Gradual loss of productivity (PL) and daily activities can be modified by effective…
Abstract Number: 2535 • 2017 ACR/ARHP Annual Meeting
Patient Outcomes from a Tertiary Center Combined Rheumatology-Dermatology Clinic
Charis Gn¹, Delaney Conway², Joanne Cunha³, Abrar Qureshi⁴, So Yeon Paek⁵ and Anthony M. Reginato⁶, ¹Division of Rheumatology, The Warren Alpert Medical School of Brown University, Providence, RI, ²Internal Medicine, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ³Division of Rheumatology, The Warren Alpert Medical School of Brown University, East Providence, RI, ⁴Dermatology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁵Departmet of Dermatology, The Warren Alpert Medical School of Brown University, Providence, RI, ⁶Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI
Background/Purpose: Many autoimmune diseases have both musculoskeletal and cutaneous manifestations, which historically have been managed separately by rheumatologists and dermatologists. Given the complex presentation of…
Abstract Number: 2536 • 2017 ACR/ARHP Annual Meeting
Comparison of Quality-of-Life, Function and Psoriasis Measures in Minimal Disease Activity and DAS28 States in Routine Care of Patients with Psoriatic Arthritis
Catherine Hughes, Nora Ng, Toby Garrood and Bruce Kirkham, Rheumatology, Guy's & St Thomas NHS Foundation Trust, London, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) often occurs with skin psoriasis (PsO). Disease activity can be measured using several tools including Minimal Disease Activity (MDA/VLMDA) or 28…
Abstract Number: 2537 • 2017 ACR/ARHP Annual Meeting
Changes in Severity, Functional Status, and Wellbeing over Time Among Individuals with Ankylosing Spondylitis (AS) in Canada: Results from the RHUMADATA® Multicentre Registry
Shelagh Szabo¹, Sara Chehab², Louis Coupal³ and Denis Choquette⁴, ¹Broadstreet HEOR, Vancouver, BC, Canada, ²Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴University of Montreal Hospital Research Centre (CRCHUM), Notre Dame Hospital Montreal, Montreal, QC, Canada
Background/Purpose: While changes in disease severity, functional status, and patient wellbeing are commonly measured in AS trials, longitudinal data from real-world cohorts are fewer; particularly…
Abstract Number: 2538 • 2017 ACR/ARHP Annual Meeting
Change in Self-Reported Health Status and Fatigue before and after the Diagnosis of Psoriatic Arthritis- the Nord-Trondelag Health Study (HUNT)
Mari Hoff¹, Tom Ivar Lund Nilsen², Ruth Stoklund Thomsen³, Agnete Malm Gulati⁴, Arthur Kavanaugh⁵ and Glenn Haugeberg⁴, ¹Rheumatolgy, University Hospital, St. Olavs Hospital, NTNU, Trondheim, Norway, ²Faculty of medicine, Department of public health and nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ³Faculty of Medicine, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ⁴NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ⁵Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that can involve skin, nails, joints, enthuses, and can be associated with systemic symptoms such as…
Abstract Number: 2539 • 2017 ACR/ARHP Annual Meeting
The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis
Arthur Kavanaugh¹, Alice B Gottlieb², Akimichi Morita³, Joseph Merola⁴, Julie Birt⁵, Chen-Yen Lin⁵, Catherine Shuler⁵ and Diamant Thaçi⁶, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Dermatology, New York Medical College, Vallhalla, NY, ³Dept of Geriatric & Environmental Dermatology, Nagoya City Univ Medical School, Nagoya, Japan, ⁴Clinical Unit for Research Innovation & Trials, Harvard Medical School, Boston, MA, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein Campus Luebeck, Ratzeburger Allee, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease affecting peripheral and axial joints. For patients with active psoriasis, the added burden of skin…
Abstract Number: 2540 • 2017 ACR/ARHP Annual Meeting
Impact of Sleep on Measures of Disease Activity in Psoriatic Arthritis
Sayanika Kaur¹ and Martin J. Bergman^2,3, ¹Internal Medicine, Mercy Catholic Medical Center, Lansdowne, PA, ²Drexel University College of Medicine, philadelphia, PA, ³Drexel University College of Medicine, Ridley Park, PA
Background/Purpose: The impact that sleep has on patients’ perception of disease activity in Psoriatic Arthritis (PsA) has been poorly understood. We assessed the association between…
Abstract Number: 2541 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Patient Acceptable Symptom State (PASS) and Disease Activity in Patients with Psoriatic Arthritis (PsA)
Jeanie Z. Fei¹, Justine (Yang) Ye¹, Anthony V. Perruccio², Dafna D Gladman³ and Vinod Chandran⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: PASS is the highest level of symptoms beyond which patients consider themselves well. Psoriatic Arthritis Disease Activity Score (PASDAS) is a recently developed composite…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].